

1 Wastewater surveillance for COVID-19 response at  
2 multiple geographic scales: Aligning wastewater and  
3 clinical results at the census-block level and  
4 addressing pervasiveness of qPCR non-detects

5 *Hannah Safford,<sup>1</sup> Rogelio E. Zuniga-Montanez,<sup>1</sup> Minji Kim,<sup>2</sup> Xiaoliu Wu,<sup>3</sup> Lifeng Wei,<sup>3</sup> James*  
6 *Sharpnack,<sup>3</sup> Karen Shapiro,<sup>2</sup> Heather Bischel<sup>1\*</sup>*

7 <sup>1</sup> Department of Civil and Environmental Engineering, University of California Davis, Davis,  
8 California 95616, United States


9 <sup>2</sup> School of Veterinary Medicine, University of California Davis, Davis, California 95616, United  
10 States

11 <sup>3</sup> Department of Statistics, University of California Davis, Davis, California 95616, United States

12 **Keywords:** Bayesian analysis, multiple imputation, qPCR non-detects, SARS-CoV-2,  
13 wastewater-based epidemiology, wastewater monitoring

14

15 **Abstract**



16

17 Wastewater surveillance is a useful complement to clinical testing for managing COVID-19. While

18 good agreement has been found between community-scale wastewater and clinical data, little is

19 known about sub-community relationships between the two data types. Moreover, effects of non-

20 detects in qPCR wastewater data have been largely overlooked. We used data collected from

21 September 2020–June 2021 in Davis, California (USA) to address these gaps. By applying a

22 predictive probability model to spatially disaggregate clinical results, we compared wastewater

23 and clinical data at the community scale, in 16 sampling zones isolating city sub-regions, and in

24 seven zones isolating high-priority building complexes or neighborhoods. We found reasonable

25 agreement between wastewater and clinical data at all scales. Greater activity (i.e., more frequent

26 detections) in clinical data tended to be mirrored in wastewater data. Small, isolated clinical-data

27 spikes were often matched as well. We also developed a method for handling such non-detects

28 using multiple imputation and compared results to (i) single imputation using half the qPCR limit

29 of detection, (ii) single imputation using maximum qPCR cycle number, and (iii) non-detect

30 censoring. Apparent wastewater trends were significantly influenced by non-detect handling.

31 Multiple imputation improved correlation relative to single imputation, though not necessarily

32 relative to censoring.

33 **Text**

34 **Introduction**

35 Wastewater surveillance (also known as wastewater-based epidemiology, or WBE) has become  
36 widely recognized as a useful complement to clinical testing for managing COVID-19. Relative  
37 to large-scale diagnostic testing, wastewater surveillance offers a less resource-intensive way to  
38 monitor COVID-19 infections and spread among large numbers of people. Wastewater  
39 surveillance is also unbiased, capturing data on entire populations rather than just the subset of  
40 individuals who come in for clinical testing [1].

41 Most studies to date comparing wastewater and clinical data have focused on the community  
42 scale; i.e., comparing trends in data collected from the influent to a given wastewater treatment  
43 plant (WWTP) to trends in data collected from clinical tests of a subpopulation served by that  
44 WWTP. Such studies have frequently found good agreement between the two data sources. But  
45 little is known about relationships between wastewater and clinical data at sub-community levels.  
46 A first objective of this study was to advance and inform uses of wastewater surveillance at  
47 multiple scales for pandemic response. For instance, comparing data trends for wastewater  
48 collected from different neighborhoods could help public-health officials strategically allocate  
49 resources such as testing, contact tracing and vaccination outreach.

50 Separately, SARS-CoV-2 RNA in wastewater samples is typically quantified using either  
51 reverse transcription-quantitative polymerase chain reaction (RT-qPCR) or RT-droplet digital  
52 PCR (RT-ddPCR) [2]. While RT-ddPCR is becoming more popular for wastewater surveillance  
53 [3] due to its greater specificity and sensitivity [4,5], many laboratories continue to use RT-qPCR  
54 due to the higher cost and time requirements of RT-ddPCR and the large upfront capital investment  
55 of ddPCR instrumentation.

56 Bivins et al. (2021) recently drew attention to how variability in RT-qPCR methods and  
57 reporting affects results and interpretation [6]. An additional and important source of variability  
58 not considered by these authors is how non-detects are handled. qPCR non-detects occur routinely  
59 for reasons including low or zero starting target abundance, poor assay design/performance, or  
60 human error [7,8]. There is no current consensus on how to best manage qPCR non-detects.  
61 Researchers, whether through scientific software or manual analysis, typically handle non-detects  
62 either using single imputation (setting all non-detects equal to a constant value such as the mean  
63 of detected replicates, half the detection limit, or zero) or by censoring (excluding non-detects from  
64 analysis altogether) [8].

65 Unfortunately, both single imputation and censoring can substantially bias qPCR results [8]. The  
66 biasing effect is amplified when, as is often the case for wastewater data, the target is present in  
67 low concentrations to begin with. A second objective of this study was to demonstrate how  
68 different non-detect handling methods can affect apparent wastewater data trends, and to explore  
69 whether multiple imputation of non-detects can improve on more commonly used but less  
70 sophisticated approaches.

71

## 72 **Materials and Methods**


### 73 *Study setting and design*

74 We used wastewater data collected through the [Healthy Davis Together \(HDT\)](#) program in  
75 Davis—a small city of approximately 69,000 located in northern California—to (1) examine  
76 relationships between wastewater and clinical data at multiple spatial scales, and (2) explore the  
77 value of multiple imputation for handling qPCR non-detects.

78 HDT is a joint, multi-pronged initiative between the city of Davis and the University of  
79 California, Davis (UC Davis) for local management and mitigation of COVID-19. Beginning in  
80 November 2020, HDT made free, saliva-based PCR tests for COVID-19 available to anyone living  
81 or working in Davis. Uptake of the clinical-testing program was considerable. The fraction of  
82 Davis residents who reported receiving at least one COVID-19 test rose from 30% to 73% from  
83 September 2020 to March 2021. As of April 2021, Yolo County had performed the most tests per  
84 capita of California's 58 counties, at a rate quadruple the state median.

85 HDT also conducts wastewater surveillance at the community, sub-regional, and  
86 building/neighborhood scales (Figure 1). At the community scale, samples are collected from the  
87 influent to the City of Davis Wastewater Treatment Plant (COD WWTP). The COD WWTP  
88 captures all of Davis's municipal wastewater, with no contributions from UC Davis or from  
89 neighboring jurisdictions. At the sub-regional scale, samples are collected from sewershed nodes  
90 isolating the wastewater contributions of different geographic areas in the city. At the  
91 building/neighborhood scale, samples are collected from sewershed nodes isolating high-priority  
92 building complexes or neighborhoods identified through discussion with local officials. The HDT  
93 WBE program began in September 2020 with weekly samples collected from the COD WWTP.  
94 Zones were added and sampling frequency increased over the course of the sampling campaign  
95 (Figure S1). At full scale-up, the surveillance program sampled daily from the COD WWTP and  
96 3x/week from each of 16 sub-regional and seven building/neighborhood zones.

97



98

99 **Figure 1.** Map of sub-regional (SR; blue) and building/neighborhood (BN; purple) sampling zones  
100 for SARS-CoV-2 wastewater-based epidemiology in the city of Davis, CA. Note overlapping  
101 zones: in particular, zone SR-M overlaps the entirety of zone BN-F; zone SR-N overlaps a portion  
102 of zone SR-O and the entirety of zone SR-M; and zone SR-P overlaps the entirety of zones SR-A  
103 through SR-E as well as zones SR-O, SR-N, and SR-M.

104

#### 105 *Sample collection*

106 24-h composite samples were collected from each zone using insulated Hach™ AS950 Portable  
107 Compact Samplers (Thermo Fisher Scientific, USA) programmed to collect 30 mL of sample  
108 every 15 minutes. The bulk of samples were processed immediately, with a small number stored  
109 at 4°C for up to one week before processing.

110

111 *Sample processing*

112 Samples were pasteurized for 30 minutes at 60°C to reduce biohazard risk while preserving RNA  
113 quality. Samples were then spiked with a known concentration of  $\phi 6$  bacteriophage (strain HB104;  
114 generously provided by Samuel Díaz-Muñoz, UC Davis) as an internal recovery control [9,10].  
115 The  $\phi 6$  spike solution was prepared using previously described methods [11], modified slightly  
116 by using ATCC® Medium 129 in place of LB media. The final steps in the processing pipeline  
117 were sample concentration and extraction. From September 2020 through the end of February  
118 2021, concentration was performed via ultrafiltration through 100 kDa Amicon® Ultra-15  
119 centrifugal filter devices, and column-based extraction was performed manually using either the  
120 NucleoSpin® RNA Stool Kit (Macherey-Nagel) or the AllPrep® PowerViral® DNA/RNA Kit  
121 (Qiagen). From February 2021 through June 2021, concentration was performed using Nanotrap®  
122 Magnetic Virus Particles (Ceres Nanosciences) and the MagMAX Microbiome Ultra Nucleic Acid  
123 Isolation Kit (Thermo Fisher) coupled with the KingFisher Flex liquid-handling system (Thermo  
124 Fisher). The particle-based method was far more conducive to automation and higher throughput  
125 than the ultrafiltration-based method, and the switch was necessary to accommodate greater  
126 numbers of samples as the sampling campaign scaled up.

127 We performed a four-sample comparison of the two methods and found that while the  
128 ultrafiltration method yielded higher concentrations of the fecal-strength indicator PMMoV, the  
129 magnetic-bead method appeared to be more sensitive for SARS-CoV-2, as indicated by detection  
130 of the N1 and N2 regions of the SARS-CoV-2 nucleocapsid gene (Figure S2; Table S1). Further  
131 details on the concentration and extraction protocols are available in *SI Materials and methods*.  
132 Raw data from the methods comparison is available in *SI Methods comparison*.

133

134 *RT-qPCR*

135 Sample extracts were analyzed by one-step RT-qPCR for four targets: N1 and N2 targeting  
136 regions of the nucleocapsid (N) gene of SARS-CoV-2,  $\phi 6$  bacteriophage, and pepper mild mottle  
137 virus (PMMoV; used for normalization of SARS-CoV-2 results). Per Bivins et al. (2021) [6], the  
138 Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE)  
139 checklist for this study is included as *SI MIQE*, and additional information on the RT-qPCR assay  
140 designs is available in Tables S1–S3. Triplicate wells were run for each target of each sample.  
141 Each run included a positive plasmid control and a no-template control, both run in duplicate. Six-  
142 point master standard curves for each target (Table S4) were constructed using serial dilutions of  
143 plasmid containing the targets at known concentrations, with each dilution assayed in triplicate or  
144 quadruplicate.

145

146 *Multiple imputation of non-detects*

147 We developed and applied an expectation maximization-Markov chain Monte Carlo (EM-  
148 MCMC) model for multiple imputation of “missing” qPCR data: i.e., N1/N2 non-detects. Our  
149 multiple-imputation method for handling non-detects was inspired by the EM algorithm presented  
150 in McCall et al. (2014) [8]. Separately for each target (i.e., N1 and N2), we began by grouping  
151 results by sampling zone.<sup>1</sup> Within each zone we modeled the Ct values ( $X_{i,t}$ ) for each technical  
152 replicate (index  $i$ ) and sampling date (index  $t$ ) as independent and identically distributed. The  
153 values are modeled with a normal distribution characterized by a common variance  $\sigma_k^2$  and  
154 common prior on the mean parameters  $\theta_{i,t}$ . The normal distribution is truncated such that it is  
155 positive.

---

<sup>1</sup> The method can accommodate other types of groupings—e.g., by sampling scale.



156 We then used an empirical Bayesian approach to learn the prior for the model parameters. This  
157 approach enables discovery of hyperparameters shared by all samples from the same zone via the  
158 EM algorithm. The approach hence reduces variability in the inferred mean Ct values by specifying  
159 a common prior for all samples from a given location. Specifically, we modeled the priors for all  
160  $\theta_{i,t}$  and common  $\sigma$  as two Gamma distributions with shape and rate parameters  $\alpha_i^\theta$ ,  $\beta_i^\theta$  and  $\alpha_i^\sigma$ ,  
161  $\beta_i^\sigma$ , respectively. We estimated these hyperparameters<sup>2</sup> with the EM algorithm, which alternates  
162 between calculating the posterior distribution for the latent (i.e., model-inferred) parameters given  
163 the current hyperparameters (E step) and updating the hyperparameters using maximum likelihood  
164 based on the posterior expectation. Because closed forms for the posterior distribution do not exist  
165 for this application, we sampled from the posterior using MCMC via Python's Stan package  
166 (pystan).

167 The EM-MCMC algorithm can be summarized as:

- 168 (1) Initialize the hyperparameters  $\alpha_i^\theta$ ,  $\beta_i^\theta$ ,  $\alpha_i^\sigma$ ,  $\beta_i^\sigma$ .
- 169 (2) Generate  $T$  (a user-defined choice) Monte Carlo samples of the latent parameters  $\theta_{i,t}$  and  
170  $\sigma$  within the group using MCMC with the current hyperparameters.
- 171 (3) Compute the maximum likelihood estimates of the hyperparameters given the  $T$  sampled  
172 latent parameters (solved numerically via the `scipy.stats.gamma.fit` method).
- 173 (4) Repeat steps 2 and 3 until convergence of hyperparameters.

174 This process was carried out independently for each target and group. The Python script used for  
175 implementation is available at <https://tinyurl.com/Safford-et-al-EM-MCMC>.

176

---

<sup>2</sup> A hyperparameter is a parameter used only to influence the learning behavior of a model. Hyperparameter values are not derived from training or experimental data. By contrast, parameters are values determined by the model from analyzing input data.

177 *Data analysis*

178 For multiple imputation, qPCR results grouped by zone were fed into the EM-MCMC model  
179 initialized with the hyperparameter priors  $\alpha_i^\theta = 1$ ,  $\beta_i^\theta = 1/35$ ,  $\alpha_i^\sigma = 3$ ,  $\beta_i^\sigma = 1$ . The model was run  
180 for 20 iterations, generating  $10^4$  MCMC samples per iteration of which the first 500 were dropped.  
181 The model was then run again for one iteration (again with  $10^4$  MCMC samples and 500 drop  
182 samples) using the hyperparameter estimates. The model output contained estimated posterior  
183 mean N1 and N2 Cts ( $\bar{\theta}_i^{N1}$  and  $\bar{\theta}_i^{N2}$ ) for each sample. the N1 and N2 targets for each location/date  
184 pair. Single imputation was performed for comparison method (i) by substituting 0.05 gene copies  
185 (gc)/reaction for N1 and 0.1 gc/reaction for N2 (i.e., half the N1 and N2 LODs calculated using  
186 99% confidence level) as the target concentrations for any technical replicate yielding a non-detect.  
187 Single imputation was similarly performed for comparison method (ii) by substituting 0.010  
188 gc/reaction and 0.047 gc/reaction (values calculated from the master standard curves using the  
189 assay's maximum Ct of 45) as the target concentrations. Censoring was performed for comparison  
190 method (iii) by dropping non-detect values from N1 and N2 calculations.

191 N1, N2, and PMMoV reaction concentrations were converted to gc/L of initial sample based on  
192 effective volumes analyzed. MATLAB® software (version R2021a; MathWorks) was used for  
193 subsequent analysis. N1 and N2 concentrations were averaged into a single concentration ( $C_{N1N2}$ )  
194 per sample to facilitate data visualization and trend analysis.  $C_{N1N2}$  values were normalized using  
195 PMMoV according to the formula  $C_{norm} = \left( \frac{C_{N1N2}}{C_{PMMoV}} \right) * 10^5$ , where  $10^5$  is a scaling factor.

196 Normalized outliers were winsorized at the [1,95] percentile levels. Finally, relative normalized  
197 values were calculated separately for each non-detect handling method using the formula

198  $C_{norm,rel} = \frac{C_{norm}}{C_{norm,max}}$ , where  $C_{norm,max}$  is the maximum normalized value of all sewershed

199 samples. Relative normalized values were used to visualize and compare trends in wastewater data

200 processed using different non-detect handling methods. Because virus concentrations detected in  
201 WWTP influent differed substantially from virus concentrations detected in sewershed samples,  
202 these calculations were performed separately on sewershed and WWTP data. Values in between  
203 sampling dates were linearly interpolated to facilitate comparison of wastewater and clinical data,  
204 and the MATLAB “smoothdata” function was applied using a centered 7-day moving average.

205


### 206 *Probabilistic assignment of clinical data to sampling zones*

207 All clinical data collected by HDT’s asymptomatic community-testing program<sup>3</sup> since program  
208 inception were provided as an anonymized dataset indicating the date that each test was  
209 administered, the ZIP code and census block corresponding to the testee’s address, and whether  
210 the test was positive. Use of these data was deemed exempt from IRB review by the University of  
211 California, Davis IRB Administration. To compare clinical and wastewater data at the city/WWTP  
212 scale, we selected a subset of these data comprising all clinical-testing results for Davis ZIP codes  
213 (95616, 95617, and 95618). We designed a Python tool (available at [https://tinyurl.com/Safford-](https://tinyurl.com/Safford-et-al-Predictive)  
214 [et-al-Predictive](https://tinyurl.com/Safford-et-al-Predictive)) that combines information on municipal wastewater flows with U.S. Census  
215 Bureau data to probabilistically assign HDT asymptomatic testing results to sewershed sampling  
216 zones via three steps. First, we used the geospatial coordinates of all maintenance holes (MHs) in  
217 the Davis sewer system, along with information indicating the relative positions  
218 (upstream/downstream) of each MH, to build a graph capturing directional connections among all  
219 MHs (Figure 2A). Second, we used 2019 American Community Survey (ACS) data from the U.S.  
220 Census Bureau (UCSB) to estimate the number of people living in each census block included in

---

<sup>3</sup> UC Davis also conducts a testing program open only to UC Davis students and employees. Data from this program were not included in the dataset used for this study.

221 the HDT clinical-testing dataset. We assume that each person in each census block produces the  
222 same amount of wastewater (a “unit”) each day, and that each person has an equal probability of



223 discharging the wastewater unit to each MH located within the block (Figure 2B).

224 **Figure 2.** (A) Visualization of the connection graph showing all maintenance holes (MHs) in  
225 the City of Davis sewershed. Orange dots indicate all MHs upstream of a target MH (in red). (B)  
226 Illustration of how the connection graph is used to probabilistically assign positive clinical-test  
227 results from census blocks to sewershed monitoring zones for the purpose of comparing trends in  
228 wastewater data to trends in clinical data. In the illustration, the sewershed monitoring zone  
229 covered by the sampler location at bottom and indicated in blue spans two census blocks. The  
230 census block on the left has a population of six and one positive test result; the census block on  
231 the right has a population of four and no positive test results. Tracking flow through the connection  
232 graph results in a predicted 0.33 infections captured by the sampler.

233

234

235 Finally, we used the connection graph to probabilistically assign positive clinical-testing results  
236 from census blocks to sewershed monitoring zones. We excluded Zones SR-F, SR-G, BN-F, and  
237 BN-G from the probabilistic case assignment due to unreliable population data. Using the UCSB  
238 data, our tool estimated the populations of each of these zones to be less than 100: these estimates  
239 are unreasonably low given our *a priori* knowledge of the study setting. For Zones SR-F and BN-  
240 F, the unreliability could be because of the existence of potentially hard-to-count communities:  
241 several apartment complexes targeted at low-income renters in the former and a mobile-home park  
242 for senior citizens in the latter [12]. For Zones SR-F and BN-G, the unreliability can be attributed  
243 to the fact that the 2010 Decennial Census underlies the 2019 ACS. Zone SR-F comprises a large  
244 residential development that had not yet been built at the time that the 2010 Decennial Census was  
245 conducted. Zone BN-G largely comprises off-campus student housing that was under renovation  
246 at the same time. Population estimates for all other zones are provided in Table S7.

247

## 248 **Results and Discussion**

### 249 *Sample collection and processing*

250 We analyzed 964 wastewater samples collected during the sampling campaign, comprising 77  
251 samples from the COD WWTP, 695 from the sub-regional zones, and 191 from the  
252 building/neighborhood zones. Overall, 204 samples (21%)—collected from September 24, 2020  
253 through March 1, 2021—were processed using ultrafiltration + manual extraction and the  
254 remaining 760 (79%)—collected from February 24, 2021 through June 11, 2021—were processed  
255 using magnetic beads.

256

### 257 *Virus recovery and detection*

258 Mean  $\phi_6$  recovery was  $1.30 \pm 0.28\%$  across all samples, in line with values reported elsewhere  
259 [13]. At least one sample from each monitoring site and a total of 377 samples across all sites  
260 tested positive for SARS-CoV-2 (i.e., N1 or N2 above LOD in at least one technical replicate).  
261 Non-detect replicates were common even among positive samples; only 32 samples were positive  
262 for all N1 and N2 technical replicates.

263 N1 and N2 non-detect percentages were similar and inversely proportional to sampling scale  
264 (Table S5). This suggests that reliable detection of SARS-CoV-2 may become more challenging  
265 the further upstream in a sewershed that sampling is conducted. Pepper mild mottle virus  
266 (PMMoV) non-detects were never observed, indicating that the high percentages of N1/N2 non-  
267 detects can be attributed to frequently low abundance of SARS-CoV-2 in the wastewater samples  
268 rather than a systematic problem with the qPCR protocols used. This is further supported by (1)  
269 inclusion of N1 and N2 positive controls for every qPCR run, and (2) the fact that samples yielding  
270 higher numbers of positive technical replicates also exhibited lower Cts on average for those  
271 replicates (Table S6)—i.e., non-detects were more common when the target was present at lower  
272 concentrations.

### 273 *Multiple imputation of non-detects*

274 Trace plots of posterior means generated by the EM-MCMC model over time generally showed  
275 good convergence. Trace plots of the MCMC samples exhibited no obvious patterns, indicating  
276 strong mixing of the Markov chains (Figure S3). Table 1 summarizes model output. The top half  
277 of the table shows that the number of positive replicates for a given sample exhibit a weak negative  
278 correlation with average standard deviations of N1 and N2 posterior mean Cts. This indicates that  
279 as the number of positive replicates increases, so too does the model's confidence in its estimate  
280 of the "true" Ct. The bottom half of the table shows that the more positive replicates of a sample

281 there are, the closer the average of those replicates is likely to be to the posterior mean Ct. The  
 282 model output also shows that sampling scale exhibits a weak positive correlation with (1) standard  
 283 deviations and (2) differences between the posterior mean and the average of positive replicates.  
 284 This is likely because larger overall numbers of non-detects at higher-granularity sampling zones  
 285 yield larger estimates for the per-zone variance. The very large posterior mean Cts for samples  
 286 with zero positive replicates indicate that the model predicts that these samples contain essentially  
 287 zero SARS-CoV-2 RNA.

288 **Table 1.** Summary of imputation model output

Average imputed standard deviation								
Sampling scale	N1*				N2*			
	Number of positive replicates				Number of positive replicates			
	0	1	2	3	0	1	2	3
Community	7.85 (0.10)	3.27 (0.05)	2.85 (0.07)	2.71 (0.03)	7.84 (0.09)	3.29 (0.14)	2.91 (0.09)	2.73 (0.04)
Sub-regional	11.22 (3.89)	3.90 (0.81)	3.28 (0.57)	2.92 (0.36)	11.30 (3.85)	3.79 (0.66)	3.27 (0.53)	2.83 (0.33)
Building/neighborhood	20.15 (4.15)	4.69 (0.90)	3.42 (0.57)	2.94 (0.28)	20.01 (4.48)	4.25 (0.64)	3.69 (0.62)	3.20 (0.50)
Overall	13.78 (5.83)	3.99 (0.87)	3.24 (0.55)	2.89 (0.33)	13.73 (5.78)	3.79 (0.66)	3.25 (0.53)	2.86 (0.35)
Average difference in mean Cts								
Sampling scale	N1*				N2*			
	Number of positive replicates				Number of positive replicates			
	0	1	2	3	0	1	2	3
Community	13.66 (0.06)	8.29 (0.51)	3.82 (1.29)	1.53 (0.17)	13.64 (0.06)	6.89 (1.20)	3.86 (0.55)	1.41 (0.15)
Sub-regional	20.47 (7.38)	8.99 (1.49)	4.73 (1.26)	1.96 (1.02)	20.62 (7.31)	7.97 (1.34)	4.37 (0.87)	1.58 (0.58)
Building/neighborhood	37.63 (7.94)	10.26 (1.45)	4.94 (0.87)	1.88 (0.96)	37.37 (8.48)	8.41 (1.23)	4.98 (0.78)	1.76 (0.63)
Overall	25.37 (11.18)	9.16 (1.52)	4.65 (1.26)	1.89 (0.93)	25.27 (11.07)	7.90 (1.36)	4.34 (0.85)	1.57 (0.55)

\*Upper value indicates average; lower (parentetical) value indicates standard deviation.

289

290 *Comparison of clinical and wastewater data*

291 Davis is a small community that experienced a relatively low COVID-19 burden during this  
 292 study, daily numbers of HDT-reported cases were generally low. Double-digit numbers of

293 confirmed cases were reported on only 11 of the 234 days included in this study, and days on  
294 which the number of confirmed cases was zero or one were common. Probabilistically assigned  
295 case levels at the sub-regional and building/neighborhood scales were frequently fractional and  
296 near zero as a result. Figure S4 co-plots the clinical data and normalized SARS-CoV-2  
297 concentrations for each sampling zone.

298 Correlations between clinical and wastewater data were reasonably good at all sampling scales.  
299 Zones and time periods exhibiting greater activity (i.e., more frequent detections) in clinical data  
300 tended to also exhibit greater activity in wastewater data. We generally observed more data activity  
301 at the community and sub-regional scales than at the building/neighborhood scale, as well as more  
302 activity in bigger zones at a given scale. This finding is logical—average COVID-19 case counts  
303 will be higher in zones covering more people—but important because it indicates that the  
304 predictive probability model is reasonably successful at assigning positive cases to the appropriate  
305 sampling zones.

306 In multiple zones (e.g., BN-D, BN-E, SR-C, SR-E, and SR-I), even relatively small and isolated  
307 spikes in clinical data were matched by spikes in wastewater data. As Zulli et al. (2021) observe,  
308 parallel spikes in wastewater virus concentrations and clinical case rates recorded at the  
309 community and regional levels during the winter 2020/2021 COVID-19 surge indicate that  
310 wastewater monitoring can provide accurate information on changes in disease burden [14]. Our  
311 results provide evidence that wastewater monitoring is similarly valuable at the sub-regional and  
312 building/neighborhood levels.

313 Separately, wastewater data from most zones sampled in this study were characterized by major  
314 peaks and valleys—with a high positive result frequently occurring right after a low positive result  
315 and vice versa—rather than smooth trends. This phenomenon can be mostly attributed to low-



316 frequency sampling during the period of highest disease burden. Based on daily sampling of  
317 wastewater from multiple WWTPs in Wisconsin, Feng et al. (2021) concluded that “a minimum  
318 of two samples collected per week [is] needed to maintain accuracy in trend analysis” [15]. Due  
319 to staffing and lab-capacity constraints, however, wastewater samples for this study were only  
320 collected on a weekly basis from November through late January. Trend smoothness generally  
321 improved when sampling frequency was increased in late winter / early spring. Data from zone  
322 SR-L provide a particularly good example of how increased sampling frequency made it easier to  
323 trace trends.

324  
325 Even after sampling frequency increased, we occasionally observed isolated high-positive  
326 results that did not appear part of broader trends (e.g., for zone SR-H in late March and zone SR-  
327 F in late April). These isolated positives could be due to aberrations (such as an infected group of  
328 individuals temporarily visiting a zone or coincidental passage of a large amount of virus-rich fecal  
329 matter near an autosampler actively drawing up volume) rather than sustained community spread.  
330 This possibility cautions against basing public-health interventions on individual data points.

331 Occasional mismatches between wastewater and clinical data trends (e.g., the spike observed for  
332 clinical—but not wastewater—data in early April for Zone SR-B) have multiple possible  
333 explanations. One is that while the predictive probability model performs reasonably well, it is still  
334 at best an approximation of the number of clinically confirmed cases in each wastewater sampling  
335 zone. Furthermore, generally low COVID-19 levels in Davis yielded sparse and/or weak positive  
336 signals in the clinical data, which in turn made it difficult to perceive trends at more granular spatial  
337 levels. A more precise comparison of wastewater and clinical data would require disclosing the  
338 addresses of individuals testing positive—an unacceptable privacy violation.

339 A second explanation is that the HDT dataset used in this study is incomplete. The dataset does  
340 not include results from other COVID-19 testing opportunities available to Davis residents (e.g.,  
341 tests conducted in medical settings or through county-run testing programs). The HDT dataset also  
342 does not include results from the parallel on-campus testing program for UC Davis students and  
343 employees even though these individuals frequently reside off campus. This explanation could  
344 account for the February spike in wastewater—but not clinical—data observed for Zone BN-D,  
345 since Zone BN-D includes an apartment complex targeted at students.

346 A final explanation is that neither WBE nor clinical testing reliably capture the “true” level of  
347 COVID-19 infections in a sampling zone. WBE results can be affected by many factors, including  
348 variability in SARS-CoV-2 excretion rates [16], wastewater composition and temperature, average  
349 in-sewer travel time, per-capita water use [17], autosampler settings [18], and movement of people  
350 in and out of sampling zones. Clinical-testing results can be further biased by various types of self-  
351 selection [19,20]. Though it is impossible to precisely determine the relative contributions of these  
352 factors and biases, context can suggest which are likely to have the greatest influence in a given  
353 instance. For example, an unexplained spike in wastewater—but not clinical—data for a zone  
354 housing disproportionate numbers of individuals with characteristics that could cause lower  
355 propensity to test (e.g., limited access to transportation; low English proficiency) could be a sign  
356 of the presence of infected individuals detected through WBE but not clinical testing.

357

### 358 *Comparison of non-detect handling methods*

359 We compared our multiple-imputation method with three other, commonly used methods for  
360 handling non-detects in wastewater qPCR data:

361 (1) [**LOD<sub>0.5</sub>**]. Single imputation with half the detection limit.


362 (2) [ $C_{t_{max}}$ ]. Single imputation with the maximum qPCR cycle number.

363 (3) [ $C_{t_{avg}}$ ]. Censoring non-detects entirely (and setting average concentrations of samples  
364 with no positive replicates to zero).

365 Figure S5 co-plots the clinical data and relative normalized SARS-CoV-2 concentrations  
366 calculated using each method for each sampling zone; Figure 3 provides a representative subset of  
367 these plots.

368 The plots show that trends in normalized virus concentration can be substantially influenced by  
369 the way in which non-detects are handled. For instance, peak relative normalized virus  
370 concentrations in the WWTP data are much higher when calculated using multiple imputation than  
371 when calculated using any of the comparison methods. Conversely, relative normalized virus  
372 concentrations in samples collected at zones SR-B, SR-C, and SR-D from mid-February through  
373 mid-March are much lower when calculated using multiple imputation. These zones are all  
374 geographically proximate and of roughly equivalent size, indicating that zones with similar  
375 characteristics may be similarly susceptible to bias in non-detect handling method.

376



377 **Figure 3.** Wastewater vs. clinical data in Davis, showing effects of different methods of handling  
378 non-detects. Symbols represent individual sample results; lines represent trends (as centered 7-day  
379 moving averages). Representative suite of plots; see Figure S6 for plots from all zones.

380 We applied Spearman's rank-order correlation to quantitatively assess how well trends captured  
381 by multiple imputation and the three comparison methods match clinical-data trends. Results are  
382 summarized in Table 2. While the Spearman correlation analysis provides a framework for  
383 interpreting the data, it suffers from several limitations. These include factors discussed above,  
384 including the low COVID-19 burden in Davis, imprecision associated with the predictive  
385 probability model, and external factors that can inherently confound wastewater analysis. It is also

386 hard to definitively “match” trends in clinical and wastewater data. For instance, trends in clinical  
 387 data collected from symptomatic individuals been observed to lag trends in wastewater data  
 388 [21,22]. But it is unknown whether and to what extent this lag may apply when clinical data derives  
 389 from a large-scale asymptomatic testing program like HDT.

390 With these caveats in mind, important takeaways from the correlation analysis are as follows.  
 391 First, because the LOD<sub>0.5</sub> and Ct<sub>max</sub> methods involve a similar approach, their correlation  
 392 coefficients track more closely with each other than with the Ct<sub>avg</sub> or multiple imputation  
 393 coefficients.

**Table 2.** Spearman’s rank-order correlation coefficients between clinical cases and normalized virus concentration, by zone and non-detect handling method. Bolded rows indicate zones where wastewater surveillance began prior to the winter COVID-19 surge. As described in the text, Zones SR-F, SR-G, BN-F, and BN-G were excluded from the clinical/wastewater data comparison.

Scale	Zone	Non-detect handling method			
		LOD <sub>0.5</sub>	Ct <sub>max</sub>	Ct <sub>mean</sub>	Multiple imputation
Community	<b>WWTP</b>	<b>0.4740<sup>***</sup></b> <b>(0.000)</b>	<b>0.5049<sup>***</sup></b> <b>(0.000)</b>	<b>0.4337<sup>***</sup></b> <b>(0.000)</b>	<b>0.5457<sup>***</sup></b> <b>(0.000)</b>
Sub-regional	<b>SR-A</b>	<b>-0.2778<sup>***</sup></b> <b>(0.001)</b>	<b>-0.2932<sup>***</sup></b> <b>(0.000)</b>	<b>-0.2143<sup>***</sup></b> <b>(0.009)</b>	<b>0.0199</b> <b>(0.810)</b>
	SR-B	-0.4728 <sup>***</sup> (0.001)	-0.4951 <sup>***</sup> (0.000)	-0.5779 <sup>***</sup> (0.000)	-0.5986 <sup>***</sup> (0.000)
	SR-C	-0.1035 (0.474)	-0.1077 (0.457)	0.1675 (0.245)	0.4793 <sup>***</sup> (0.000)
	<b>SR-D</b>	<b>-0.4374<sup>***</sup></b> <b>(0.001)</b>	<b>-0.4053<sup>***</sup></b> <b>(0.003)</b>	<b>-0.4970<sup>***</sup></b> <b>(0.000)</b>	<b>-0.0937</b> <b>(0.509)</b>
	SR-E	-0.5253 <sup>***</sup> (0.000)	-0.5332 <sup>***</sup> (0.000)	-0.4904 <sup>***</sup> (0.000)	-0.6165 <sup>***</sup> (0.000)
	<b>SR-H</b>	<b>-0.0832</b> <b>(0.531)</b>	<b>-0.0979</b> <b>(0.461)</b>	<b>-0.1966</b> <b>(0.136)</b>	<b>-0.3691<sup>***</sup></b> <b>(0.004)</b>
	SR-I	0.2291 (0.102)	0.1708 (0.226)	0.2418* (0.084)	0.0280 (0.844)
	<b>SR-J</b>	<b>0.2763<sup>***</sup></b> <b>(0.001)</b>	<b>0.2865<sup>***</sup></b> <b>(0.000)</b>	<b>0.4763<sup>***</sup></b> <b>(0.000)</b>	<b>0.4067<sup>***</sup></b> <b>(0.000)</b>
	<b>SR-K</b>	<b>0.3330<sup>***</sup></b> <b>(0.000)</b>	<b>0.2923<sup>***</sup></b> <b>(0.000)</b>	<b>0.5866<sup>***</sup></b> <b>(0.000)</b>	<b>0.3694<sup>***</sup></b> <b>(0.000)</b>
	<b>SR-L</b>	<b>0.4117<sup>***</sup></b> <b>(0.000)</b>	<b>0.3809<sup>***</sup></b> <b>(0.000)</b>	<b>0.4413<sup>***</sup></b> <b>(0.000)</b>	<b>0.3782<sup>***</sup></b> <b>(0.000)</b>
	<b>SR-M</b>	<b>0.6198<sup>***</sup></b>	<b>0.6194<sup>***</sup></b>	<b>0.4881<sup>***</sup></b>	<b>0.5927<sup>***</sup></b>

		<b>(0.000)</b>	<b>(0.000)</b>	<b>(0.000)</b>	<b>(0.000)</b>
	<b>SR-N</b>	<b>0.5450<sup>***</sup></b>	<b>0.5769<sup>***</sup></b>	<b>0.7597<sup>***</sup></b>	<b>0.7220<sup>***</sup></b>
		<b>(0.000)</b>	<b>(0.000)</b>	<b>(0.000)</b>	<b>(0.000)</b>
	SR-O	-0.5702 <sup>***</sup>	-0.5768 <sup>***</sup>	-0.6666 <sup>***</sup>	-0.3343 <sup>**</sup>
		(0.000)	(0.000)	(0.000)	(0.025)
	<b>SR-P</b>	<b>0.1998<sup>**</sup></b>	<b>0.2075<sup>**</sup></b>	<b>0.6747<sup>***</sup></b>	<b>0.3970<sup>***</sup></b>
		<b>(0.037)</b>	<b>(0.030)</b>	<b>(0.000)</b>	<b>(0.000)</b>
Building/ neighborhood	BN-A	0.1174	0.0860	0.1612	-0.0871
		(0.348)	(0.492)	(0.195)	(0.487)
	BN-B	-0.2520	-0.2956 <sup>*</sup>	-0.6876 <sup>***</sup>	-0.6087 <sup>***</sup>
		(0.157)	(0.095)	(0.000)	(0.000)
	BN-C	0.6666 <sup>***</sup>	0.6699 <sup>***</sup>	0.8203 <sup>***</sup>	0.8216 <sup>***</sup>
	(0.000)	(0.000)	(0.000)	(0.000)	
	<b>BN-D</b>	<b>0.4889<sup>***</sup></b>	<b>0.5033<sup>***</sup></b>	<b>0.4847<sup>***</sup></b>	<b>0.5270<sup>***</sup></b>
		<b>(0.000)</b>	<b>(0.000)</b>	<b>(0.000)</b>	<b>(0.000)</b>
	BN-E	0.7741 <sup>***</sup>	0.7881 <sup>***</sup>	0.1969	0.3883 <sup>***</sup>
		(0.000)	(0.000)	(0.195)	(0.000)

p-values are in parentheses: \*\*\* p<0.01, \*\* p<0.05, \* p<0.1

394

395 Second, much higher correlation coefficients were generally observed for the 11 zones where  
 396 wastewater surveillance began prior to the winter COVID-19 surge. This can be explained by  
 397 greater activity in the wastewater and clinical data during the winter surge, as well as by the fact  
 398 that sampling zones added later in the campaign were generally smaller—and hence less active—  
 399 than zones added earlier. Time periods and zones with more data activity provide more positive  
 400 data points on which to perform meaningful rank-order comparisons. The larger datasets available  
 401 for zones where sampling began early also strengthen the robustness of data comparisons (as  
 402 indicated by the universally low p-values of correlation coefficients for these zones). Correlation  
 403 coefficients calculated for time periods and zones with less activity and where sampling began  
 404 later can be easily skewed by a small number of disparate results between the wastewater and  
 405 clinical data.

406 Third, the correlation analysis revealed no clear “winner” among the four non-detect handling  
 407 methods. For the 11 zones where sampling began early, correlation coefficients tended to be  
 408 weaker for the LOD<sub>0.5</sub> and Ct<sub>max</sub> methods. The Ct<sub>avg</sub> method performed the best on average across  
 409 these zones, but also performed the worst (with multiple imputation performing best) for the

410 WWTP data—the one zone where imprecision associated with probabilistic assignment of  
411 confirmed positives was not a factor, and hence where correlation between the wastewater and  
412 clinical data is arguably most meaningful.

413

#### 414 *Implications for multiscale deployment of wastewater surveillance*

415 This study demonstrates that wastewater surveillance can provide a useful complement to  
416 clinical testing at multiple levels of spatial granularity. Visual and quantitative comparison of data  
417 from HDT’s universal asymptomatic clinical-testing program with data from the initiative’s  
418 intensive wastewater-surveillance campaign revealed meaningful correlations at the community,  
419 sub-regional, and building/neighborhood scales. The predictive probability model we developed  
420 for disaggregating deidentified HDT case data by wastewater-sampling zone provides a framework  
421 that can be easily extended to support sub-community comparison of clinical and wastewater data  
422 in other settings.

423 This study also demonstrates that qPCR non-detects are an important but often overlooked  
424 determinant of apparent trends in wastewater data. Our results indicate that single imputation with  
425 a value equivalent to half the assay limit of detection, the maximum qPCR cycle number, or similar  
426 generally weakens correlation between wastewater and clinical data. Simply censoring non-detects  
427 seemed to be a better approach. We did not find clear evidence that multiple imputation of non-  
428 detects delivers consistently better correlations between wastewater and clinical data than  
429 censoring does. However, the fact that multiple imputation yielded the strongest correlation for the  
430 WWTP data suggests, as discussed above, that this approach merits further investigation. With  
431 adjustments to the algorithm, tuning parameters, and variable groupings used herein, multiple

432 imputation could support more reliable analysis of trends in wastewater data—and hence position  
433 wastewater surveillance as an even stronger weapon in the fight against pandemic spread.

434 We acknowledge two limitations of our work. First, some comparisons presented herein are  
435 incomplete because sampling zones were added over time. Only two of the seven sampling zones  
436 at the building/neighborhood scale, for instance, were active during the winter pandemic surge.  
437 Though this means that our results do not provide deep insight into the value of spatially granular  
438 wastewater surveillance during periods of peak disease spread, we note that wastewater  
439 surveillance tends to be more valuable outside of such periods—e.g., as an early-warning system  
440 when background case levels are low. Second, we did not rigorously test the effect of different  
441 data groupings when running the multiple-imputation model. Though grouping data by sampling  
442 zone is a logical choice, it is possible that alternate groupings (e.g., grouping by sampling scale,  
443 grouping temporally, pooling results from adjacent sites, etc.), coupled with appropriate tuning of  
444 model parameters, could significantly alter and perhaps improve results. Indeed, further refinement  
445 and optimization of our multiple-imputation model is needed to unlock the full potential of this  
446 promising approach to handling qPCR non-detects in wastewater data.

447



448 **Supporting Information.**

449 The following files are available free of charge.

- 450 • Additional materials and methods, including information on qPCR assay, and methods
- 451 comparison, and sampling zone populations (SI Materials and methods, figures,
- 452 tables.pdf)
- 453 • Raw data and metadata from sample collection and analysis (SI Sample data and
- 454 metadata.xlsx)
- 455 • Probabilistic assignments of clinical-testing results (SI Clinical model output.xlsx)
- 456 • Raw data from methods comparison (SI Methods comparison.xlsx)
- 457 • MIQE checklist (SI MIQE.xls)

458

459 **Corresponding Author**

460 \* [hbischel@ucdavis.edu](mailto:hbischel@ucdavis.edu), (530) 752-6772, 3109 Ghausi Hall, 480 Bainer Hall Drive, Davis,  
461 California 95616, United States

462 **Present Addresses**

463 N/A

464 **Author Contributions**

465 H. Bischel and K. Shapiro oversaw the study; M. Kim tested and optimized qPCR assays; H.  
466 Safford and R. Zuniga-Montanez performed lab work; X. Liu and J. Sharpnack designed the  
467 multiple imputation model; L. Wei and J. Sharpnack designed the predictive probability model;  
468 H. Safford analyzed data, generated figures, and drafted the manuscript; R. Zuniga-Montanez,

469 M. Kim, J. Sharpnack, K. Shapiro, and H. Bischel contributed text and edits to the final  
470 manuscript. All authors have given approval to the final version of the manuscript.

#### 471 **Funding Sources**

472 Funding to support this project was generously provided by Healthy Davis Together.

#### 473 **Notes**

474 N/A

#### 475 **Acknowledgements**

476 We acknowledge the invaluable contributions of the following individuals: L. Rueda, W. Bess, R.  
477 Pechacek, and M. Clauzel for lab support; N. Krasner for data cleanup and entry; S. Gryzcko, A.  
478 Livingston, S. Macomb, and J. Miller for coordinating sample collection; M. Nuno for input on  
479 modeling and statistical analysis. This project was carried out with the generous support of Healthy  
480 Davis Together.

481

482 **References**

- 483 1. F. Wu, A. Xiao, J. Zhang, K. Moniz, N. Endo, F. Armas, M. Bushman, P.R. Chai, C.  
484 Duvallet, T.B. Erickson, K. Foppe, N. Ghaeli, X. Gu, W.P. Hanage, K.H. Huang, W.L. Lee,  
485 K.A. McElroy, S.F. Rhode, M. Matus, S. Wuertz, J. Thompson, E.J. Alm, Wastewater  
486 surveillance of SARS-CoV-2 across 40 U.S. states from February to June 2020. *Wat. Res.*  
487 202: 117400 (2021).
- 488 2. U.S. Centers for Disease Control and Prevention, “Waterborne Disease & Outbreak  
489 Surveillance Reporting: Testing Methods.” Available at  
490 [https://www.cdc.gov/healthywater/surveillance/wastewater-surveillance/testing-](https://www.cdc.gov/healthywater/surveillance/wastewater-surveillance/testing-methods.html)  
491 [methods.html](https://www.cdc.gov/healthywater/surveillance/wastewater-surveillance/testing-methods.html). Accessed October 4, 2021.
- 492 3. Kan, A. “COVID-19 Testing at the Community Level – Digital PCR is a Key Tool.”  
493 BioInformatics. Available at [https://bioinfoinc.com/covid-19-testing-at-the-community-level-](https://bioinfoinc.com/covid-19-testing-at-the-community-level-digital-pcr-is-a-key-tool/)  
494 [digital-pcr-is-a-key-tool/](https://bioinfoinc.com/covid-19-testing-at-the-community-level-digital-pcr-is-a-key-tool/). Posted March 30, 2021.
- 495 4. M. Ciesielski, D. Blackwood, T. Clerkin, R. Gonzalez, H. Thompson, A. Larson, R. Noble,  
496 Assessing sensitivity and reproducibility of RT-ddPCR and RT-qPCR for the quantification  
497 of SARS-CoV-2 in wastewater. *J. Virol. Methods*, 297: 114230 (2021).
- 498 5. L. Falzone, N. Musso, G. Gattuso, D. Bongiorno, C.I. Palermo, G. Scalia, M. Libra, S.  
499 Stefani., Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection. *Int. J.*  
500 *Mol. Med.* 46, 3: 957–964 (2020).
- 501 6. A. Bivins, D. Kaya, K. Bibby, S.L. Simpson, S.A. Bustin, O.C. Shanks, W. Ahmed.  
502 Variability in RT-qPCR assay parameters indicates unreliable SARS-CoV-2 RNA  
503 quantification for wastewater surveillance. *Wat. Res.* 203: 117516 (2021).

- 504 7. N. Zanardi, M. Morini, M.A. Tangaro, F. Zambelli, M.C. Bosco, L. Varesio, A. Eva, D.  
505 Cangelosi. PIPE-T: a new Galaxy tool for the analysis of RT-qPCR expression data. *Sci. Rep.*  
506 9: 17550 (2019).
- 507 8. M.N. McCall, H.R. McMurray, H. Land, A. Almudevar, On non-detects in qPCR data.  
508 *Bioinformatics* 30, 16: 2310–2316 (2014).
- 509 9. A. Bivins, J. Greaves, R. Fischer, K.C. Yinda, W. Ahmed, M. Kitajima, V.J. Munster, K.  
510 Bibby, Persistence of SARS-CoV-2 in Water and Wastewater. *Environ. Sci. Technol. Lett.* 7:  
511 937–942 (2020).
- 512 10. N. Aquino de Carvalho, E.N. Stachler, N. Cimabue, K. Bibby, Evaluation of Phi6 Persistence  
513 and Suitability as an Enveloped Virus Surrogate. *Environ. Sci. Technol.* 51, 15: 8692–8700  
514 (2017).
- 515 11. R.S. Kantor, K.L. Nelson, H.D. Greenwald, L.C. Kennedy, Challenges in Measuring the  
516 Recovery of SARS-CoV-2 from Wastewater. *Environ. Sci. Technol.* 55, 6: 3514–3519  
517 (2021).
- 518 12. V. Hsieh, T. Thorman, 2020 Census: Where Are California’s Hard-to-Count Communities?  
519 Public Policy Institute of California. Available at: [https://www.ppic.org/blog/2020-census-  
520 where-are-californias-hard-to-count-communities/](https://www.ppic.org/blog/2020-census-where-are-californias-hard-to-count-communities/). Posted August 1, 2018.
- 521 13. B.M. Pecson, E. Darby, C.N. Haas, Y.M. Amha, M. Bartolo, R. Danielson, Y. Dearborn, G.  
522 Di Giovanni, C. Ferguson, S. Fevig, E. Gaddis, D. Gray, G. Lukasik, B. Mull, L. Olivas, A.  
523 Olivieri, Y. Qu, SARS-CoV-2 Interlaboratory Consortium, Reproducibility and sensitivity of  
524 36 methods to quantify the SARS-CoV-2 genetic signal in raw wastewater: findings from an

- 525 interlaboratory methods evaluation in the U.S. *Environ. Sci.: Water Res. Technol.* 7: 504–520  
526 (2021).
- 527 14. A. Zulli, A. Pan, S.M. Bart, F.W. Crawford, E.H. Kaplan, M. Cartter, A.I. Jo, D. Cozens, M.  
528 Sanchez, D.E. Brackney, J. Peccia, Predicting daily COVID-19 case rates from SARS-CoV-2  
529 RNA concentrations across a diversity of wastewater catchments. *medRxiv* preprint (2021).
- 530 15. S. Feng, A. Roguet, J.S. McClary-Gutierrez, R.J. Newton, N. Kloczko, J.G. Meiman, S.L.  
531 McLellan, Evaluation of Sampling, Analysis, and Normalization Methods for SARS-CoV-2  
532 Concentrations in Wastewater to Assess COVID-19 Burdens in Wisconsin Communities.  
533 *Environ. Sci. Technol. Water* 1, 8: 1955–1965 (2021).
- 534 16. Y. Chen, L. Chen, Q. Deng, G. Zhang, J. Wu, L. Ni, Y. Yang, B. Liu, W. Wang, C. Wei, J.  
535 Yang, G. Ye, Z. Cheng, The presence of SARS-CoV-2 RNA in the feces of COVID-19  
536 patients. *J. Med. Virol.* 92, 7: 833–840 (2020).
- 537 17. O.E. Hart, R.U. Halden, Computational analysis of SARS-CoV-2/COVID-19 surveillance by  
538 wastewater-based epidemiology locally and globally: Feasibility, economy, opportunities and  
539 challenges. *Sci. Tot. Environ.* 730: 138875 (2020).
- 540 18. Ort, M.G. Lawrence, J. Rieckermann, A. Joss, Sampling for Pharmaceuticals and Personal  
541 Care Products (PPCPs) and Illicit Drugs in Wastewater Systems: Are Your Conclusions  
542 Valid? A Critical Review. *Environ. Sci. Technol.* 44: 6024–6035 (2010).
- 543 19. S. Georganas, A. Velias, S. Vadoros S., Debiasing Covid-19 prevalence estimates. *medRxiv*  
544 preprint (2021).

- 545 20. G.J. Griffith, T.T. Morris, M.J. Tudball, A. Herbert, G. Mancano, L. Pike, G.C. Sharp, J.  
546 Sterne, T.M. Palmer, G.D. Smith, K. Tilling, L. Zuccolo, N.M. Davies, G. Hemani, Collider  
547 bias undermines our understanding of COVID-19 disease risk and severity. *Nat. Commun.*  
548 11: 5749 (2020).
- 549 21. F. Wu, A. Xiao, J. Zhang, K. Moniz, N. Endo, F. Armas, R. Bonneau, M.A. Brown, M.  
550 Bushman, P.R. Chai, C. Duvallet, T.B. Erickson, K. Foppe, N. Ghaeli, X. Gu, W.P. Hanage,  
551 K.H. Huang, W.L. Lee, M. Matus, K.A. McElroy, J. Nagler, S.F. Rhode, M. Santillana, J.A.  
552 Tucker, S. Wuertz, S. Zhao, J. Thompson, E.J. Alm. SARS-CoV-2 titers in wastewater  
553 foreshadow dynamics and clinical presentation of new COVID-19 cases. *medRxiv preprint*  
554 (2020).
- 555 22. D.A. Larsen, K.R. Wigginton. Tracking COVID-19 with wastewater. *N. Biotechnol.* 38:  
556 1151–1153 (2021).

557

558 **Briefs**

559 N/A

560 **Synopsis**

561 Analysis of how multiscale wastewater surveillance can inform pandemic response and protect  
562 public health.